Witnessing the stock’s movement on the chart, on Thursday, X4 Pharmaceuticals Inc (NASDAQ: XFOR) set off with pace as it heaved 4.56% to $0.50, before settling in for the price of $0.48 at the close. Taking a more long-term approach, XFOR posted a 52-week range of $0.26-$1.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been -25.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 73.95%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 76.02%. This publicly-traded company’s shares outstanding now amounts to $168.51 million, simultaneously with a float of $117.62 million. The organization now has a market capitalization sitting at $85.71 million. At the time of writing, stock’s 50-day Moving Average stood at $0.5837, while the 200-day Moving Average is $0.6891.
X4 Pharmaceuticals Inc (XFOR) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. X4 Pharmaceuticals Inc’s current insider ownership accounts for 31.03%, in contrast to 36.18% institutional ownership. According to the most recent insider trade that took place on Jan 24 ’25, this organization’s President and CEO sold 76,473 shares at the rate of 0.45, making the entire transaction reach 34,719 in total value, affecting insider ownership by 1,087,386. Preceding that transaction, on Jan 24 ’25, Company’s Chief Financial Officer sold 74,773 for 0.45, making the whole transaction’s value amount to 33,947. This particular insider is now the holder of 0 in total.
X4 Pharmaceuticals Inc (XFOR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
X4 Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 76.02% and is forecasted to reach -0.50 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 11.43% through the next 5 years, which can be compared against the 73.95% growth it accomplished over the previous five years trading on the market.
X4 Pharmaceuticals Inc (NASDAQ: XFOR) Trading Performance Indicators
Let’s observe the current performance indicators for X4 Pharmaceuticals Inc (XFOR). It’s Quick Ratio in the last reported quarter now stands at 4.80. The Stock has managed to achieve an average true range (ATR) of 0.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 76.53.
In the same vein, XFOR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.09, a figure that is expected to reach -0.17 in the next quarter, and analysts are predicting that it will be -0.50 at the market close of one year from today.
Technical Analysis of X4 Pharmaceuticals Inc (XFOR)
Going through the that latest performance of [X4 Pharmaceuticals Inc, XFOR]. Its last 5-days volume of 1.89 million was inferior to the volume of 5.76 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 9.93% While, its Average True Range was 0.0802.
Raw Stochastic average of X4 Pharmaceuticals Inc (XFOR) in the period of the previous 100 days is set at 38.13%, which indicates a major rise in contrast to 18.90% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 209.74% that was higher than 200.29% volatility it exhibited in the past 100-days period.
